secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001104659-25-001679
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Camp4 Therapeutics reports positive Phase 1 SAD safety data for CMP-CPS-001, enables MAD dose escalation
--------------------------------------------------------------------------------

- Phase 1 SAD portion completed: 48 healthy volunteers, 32 received CMP-CPS-001; no serious adverse events, no maximum tolerated dose reached.
- All treatment-emergent adverse events were Grade 1 or 2; most common: headache (6), nausea (4).
- Safety Review Committee approved dose escalation and initiation of MAD Cohort 3.
- Cash runway into Q2 2026; upcoming milestones: MAD data 2H'25, SYNGAP1 GLP tox studies in '25.
- Corporate slide deck highlights RAP platform, pipeline, and strategic collaboration; IPO completed October 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000110465925001679/0001104659-25-001679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000110465925001679/tm252128d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer